Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01908595 · ClinicalTrials.gov registry record · Phase 3
Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis
A Phase 3 study of Psoriasis, sponsored by Maruho North America.
- Completed
- Registry status
- Phase 3
- Development phase
- 480
- Enrollment target
- 20
- Study locations
NCT01908595: Completed Phase 3 study of Psoriasis, sponsored by Maruho North America.
NCT01908595 is a Phase 3 study of Psoriasis that has completed, run by Maruho North America. The registered enrollment target is 480 participants, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target. The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01908595, a Phase 3 study of Psoriasis, has completed, sponsored by Maruho North America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 480 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
Conditions Studied
Interventions
- DRUG M518101
Study Locations (20)
Florida
- Dermatology and Aesthetic Center Skin Care - Boca Raton
- Jacksonville Center for Clinical Research - Jacksonville
- FXM Research Miramar - Miramar
- Renstar Medical Research - Ocala
- USF Health Morsani Center for Advanced Healthcare - Tampa
California
- Bakersfield Dermatology and Skin Cancer Medical Group - Bakersfield
- Dermatology Research Associates - Los Angeles
- Medical Center for Clinical Research - San Diego
- ATS Clinical Research - Santa Monica
North Carolina
- PMG research of raleigh - Cary
- PMG Research of Wilmington - Wilmington
Arizona
- Agave Clinical Research - Mesa
Colorado
- Horizons Clinical Research Center - Denver
Georgia
- Peachtree Dermatology Associates Research Center - Atlanta
Illinois
- Northshore University Health System - Skokie
Indiana
- South bend clinic - South Bend
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
What the finished NCT01908595 record still lists
NCT01908595 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 485-participant average among 125 other Psoriasis trials with a reported enrollment target.
The record links to 1 condition, with Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which M518101 is the first listed.
NCT01908595 names 20 study sites across 12 states, led by Florida, California, North Carolina.
Frequently Asked Questions
What is clinical trial NCT01908595 about?
NCT01908595 is a clinical study titled "Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis". This study is to evaluate the efficacy and safety for long term use of M518101 in subjects with plaque psoriasis.
What is the current status of trial NCT01908595?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 480 participants. The study started on 2013-08. Estimated completion is 2015-05.
What conditions does trial NCT01908595 study?
This clinical trial studies the following conditions: Psoriasis.
What interventions are being tested in trial NCT01908595?
The interventions under investigation include: M518101 (DRUG).
Who is sponsoring clinical trial NCT01908595?
This trial is sponsored by Maruho North America, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01908595 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01908595's enrollment target sits among peer trials
480 20th of 125 higher than 106 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977
ACTIVE NOT RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia